5 results
The purpose of this study is to investigate the effect of treatment with two courses of chemotherapy followed by immunotherapy. Immune therapy stimulates the body's immune response directed against the tumor. In addition, the goal is to…
The purpose of this study is to allow collection of safety and tolerability data in subjects benefitting from treatment with spartalizumab as a single agent or in combination with other study treatments in a pre-defined (Appendix Section 16.1)…
This first-in-man study will investigate the safety and tolerability as well as establish a recommended dose of INCB081776 as a monotherapy (Part 1) and then in combination with INCMGA00012 (Part 2) in participants with advanced malignancies. During…
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
To determine the efficacy of the combinations of retifanlimab + INCAGN02385 (TG2) and retifanlimab + INCAGN02385 + INCAGN02390 (TG3) compared with retifanlimab alone (TG1) in the overall study population.